RANITIDINE PRODUCTS WERE WITHDRAWN FROM KUWAIT MARKETS AFTER 4 MONTHS OF RESEARCHES
The Kuwaiti Ministry of Health MOH has decided to withdraw of Ranitidine Products based on FDA recommendation as it has more N-Nitroso dimethylamine NDMA.
In September 2019 MOH stopped registering the same until they finally decide based on the research.
TO PREVENT THE MISUSE OR MONOPOLY
As part of the Precautionary Measures, the Kuwaiti Ministry of Health MOH has announced the withdrawal of all medicine has hydroxy from all pharmacies and keeping it ONLY available in the governmental and national hospitals; to prevent the misusage or monopoly.
liability and disclaimer
Qmaizen Quality is fully responsible for all information and updates provided in this newsletter and if you wish to have more details on a specific subject, have any comments or need more clarifications about the sources, please contact email@example.com
The main purpose of this newsletter is to keep you posted with all updates about regulations, compliance and certification in the MENA region, but we don’t ensure 100% that all information is provided, as we filtered them, however, we ensure the 100% accuracy, so kindly forgive us if anything is missing.
All the information provided are quoted and diverted from official authorities’ channels, and all original rights are reserved to them, however any rephrasing or reordering have been done by Qmaizen Quality, is to suit the newsletter’s purpose.
The material and information contained in this newsletter is for general information purposes only. You shouldn’t rely upon these material and information as a basis for making any business, legal or any other decisions.